博士. ファウチはCOVID-19リバウンドを経験した後、パクスロビッドの2番目のコースを取ります

博士. ファウチはCOVID-19リバウンドを経験した後、パクスロビッドの2番目のコースを取ります

博士. アンソニー・ファウチ, 81, says hisinteresting coursewith COVID-19 is becomingmore and more typical.

ファウチ, who regularly gets tested for COVID, continued to swab after completing his five-day course of the Pfizer antiviral, パクスロビッド, 今月上旬. He tested negative for three consecutive days. On the fourth day, 彼 “reverted back to positive,” 彼は言い​​ました Foreign Policy‘s Global Health Forum.

The director of the National Institute of Allergy and Infectious Diseases says when he tested positive again, he progressively started to feelmuch worse than the first go around,” referring to his mild symptoms when he contracted COVID-19 two weeks ago. Due to the worsening of symptoms, Fauci started another pack of Paxlovid.

火曜日に, Fauci confirmed that he was on his fourth day of hissecond course of Paxlovid.He added that he isnot complete[ly] without symptomsbut does notfeel acutely ill.

It was sort of what people are referring to as a ‘Paxlovid rebound,'” ファウチは言った.

パクスロビッド

パクスロビッド
クレジット: ゲッティイメージズによるファビアンソマー/写真同盟

5月, The Centers for Disease Control and Prevention issued a 健康勧告 to update healthcare providers on Paxlovid rebound cases. In the advisory, the CDC stated thatPaxlovid treatment helps prevent hospitalization and death due to COVID-19. COVID-19 rebound has been reported to occur between 2 と 8 days after initial recovery and is characterized by a recurrence of COVID-19 symptoms or a new positive viral test after having tested negative.

The CDC recommends thatpeople with COVID-19 rebound should follow CDC recommendations regarding isolation of infected patients regardless of treatment with an antiviral agent and/or previous isolation after the initial infection.

ストーリーを見逃すことはありません—サインアップしてください PEOPLEの無料の日刊ニュースレター PEOPLEが提供する最高のものを最新の状態に保つ, ジューシーな有名人のニュースから説得力のあるヒューマンインタレスト記事まで.

水曜日に, ファウチ, who is fully vaccinated and doubly boosted, clarified to ニューヨークタイムズ それ, “Paxlovid did what it was supposed to do,” by reducing the severity of symptoms which ultimately kept him out of the hospital.

CDCによれば, “Paxlovid continues to be recommended for early-stage treatment of mild to moderate COVID-19 among persons at high risk for progression to severe diseases.